Advertisement

Сертикан

Основна информация

  • Търговско наименование:
  • Сертикан (Certican)
  • дозиране:
  • 0,1 mg
  • Лекарствена форма:
  • диспергиращи се таблетки
  • Композиция:
  • диспергиращи се таблетки 0,1 mg
  • Използвай за:
  • Хората
  • Вид на лекарството:
  • алопатични наркотици
Advertisement

Документи

Локализация

  • Предлага се в:
  • Сертикан (Certican)
    България
  • Език:
  • български

Друга информация

Състояние

  • Източник:
  • Изпълнителна агенция по лекарствата - Bulgarian Drug Agency - Bulgaria
  • Последна актуализация:
  • 09-08-2016

Листовка за пациента


13-2-2018

Opinion/decision on a Paediatric investigation plan (PIP):    Votubia, Everolimus, Therapeutic area: Neurology

Opinion/decision on a Paediatric investigation plan (PIP): Votubia, Everolimus, Therapeutic area: Neurology

Europe - EFSA - European Food Safety Authority EFSA Journal

26-1-2018

ZORTRESS (Everolimus) Tablet [Novartis Pharmaceuticals Corporation]

ZORTRESS (Everolimus) Tablet [Novartis Pharmaceuticals Corporation]

Updated Date: Jan 26, 2018 EST

US - DailyMed

11-5-2017

Long-Lasting Effect of Everolimus in Tuberous Sclerosis

Long-Lasting Effect of Everolimus in Tuberous Sclerosis

Improvements in seizures documented earlier in patients with tuberous sclerosis complex (TSC) taking everolimus (Afinitor, Novartis) in the phase 3 EXIST-3 trial have continued during an open-label extension phase of the trial.

US - RxList

20-3-2017

FDA Warns of CV Event Risk With Absorb BVS

FDA Warns of CV Event Risk With Absorb BVS

The FDA is investigating the significant increase in major adverse cardiac events (MACE) seen for the everolimus-eluting bioresorbable vascular scaffold (Absorb BVS, Abbott Vascular) vs everolimus-eluting metal stent (Xience, Abbot Vascular) in 2-year data from the ABSORB 3 trial, the agency said in a letter to clinicians published today. It approved the novel BVS scaffold in July 2016.

US - RxList

Advertisement